Direct Comparison of the Efficacy and Safety of Oral Treatments with Oleylphosphocholine (OlPC) and Miltefosine in a Mouse Model of L. major Cutaneous Leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 8, Issue 9, 2014, Pages

  Fortin, Anny ^a,b   Caridha, Diana P ^c   Leed, Susan ^c   Ngundam, Franklyn ^c   Sena, Jenell ^c   Bosschaerts, Tom ^b   Parriott, Sandi ^c   Hickman, Mark R ^c   Hudson, Thomas H ^c   Grogl, Max ^c  

^a MCGILL UNIVERSITY   (Canada)

^b Dafra Pharma Research Development   (Belgium)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CHOLINE DERIVATIVE; FLUCONAZOLE; MILTEFOSINE; OLEYLPHOSPHOCHOLINE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; PHOSPHATIDYLCHOLINE; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; IMAGING SYSTEM; IN VIVO IMAGING SYSTEM; IN VIVO STUDY; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PARASITE LOAD; SKIN LEISHMANIASIS; ULCER HEALING; WEIGHT GAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; LEISHMANIASIS, CUTANEOUS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PHOSPHATIDYLCHOLINES; PHOSPHORYLCHOLINE;

EID: 84907573454     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003144     Document Type: Article

References (18)

1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873–882.
2. WHO (2010) Control of the leishmaniases. World Health Organ Tech Rep Ser 949: 1–186.
3. Goto H, Lauletta Lindoso JA, (2012) Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am 26: 293–307.
4. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
5. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111–126.
6. Croft SL, Seifert K, Yardley V, (2006) Current scenario of drug development for leishmaniasis. Indian J Med Res 123: 399–410.
7. van Griensven J, Diro E, (2012) Visceral leishmaniasis. Infect Dis Clin North Am 26: 309–322.
8. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ, (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 67: 2576–2597.
9. Fortin A, Hendrickx S, Yardley V, Cos P, Jansen H, et al. (2012) Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis. J Antimicrob Chemother 67: 2707–2712.
10. Grogl M, Hickman M, Ellis W, Hudson T, Lazo JS, et al. (2013) Drug discovery algorithm for cutaneous leishmaniasis. Am J Trop Med Hyg 88: 216–221.
11. Anonymous (1996) Guide for the care and use of laboratory animals. National Research Council, Washington, DC.
12. Herwaldt BL, (1999) Miltefosine-the long-awaited therapy for visceral leishmaniasis? N Engl J Med 341: 1840–1842.
13. Croft SL, Olliaro P, (2011) Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect 17: 1478–1483.
14. Velez I, López L, Sánchez X, Mestra L, Rojas C, et al. (2010) Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 83: 351–356.
15. Soto J, Berman J, (2006) Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 100 Suppl 1: S34–S40.
16. Hernandez L, Gálvez R, Montoya A, Checa R, Bello A, et al. (2014) First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum. Parasitol Res 113: 157–164.
17. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, et al. (2002) Fluconazole for the Treatment of Cutaneous Leishmaniasis Caused by Leishmania major. N Engl J Med 346: 891–895.
18. Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MM, (2011) High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis 53: 693–695.